<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37452914</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1534-6307</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Current rheumatology reports</Title><ISOAbbreviation>Curr Rheumatol Rep</ISOAbbreviation></Journal><ArticleTitle>Flares in Lupus Nephritis: Risk Factors and Strategies for Their Prevention.</ArticleTitle><Pagination><StartPage>183</StartPage><EndPage>191</EndPage><MedlinePgn>183-191</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11926-023-01109-6</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW">Discuss the prognostic significance of kidney flares in patients with lupus nephritis, associated risk factors, and possible preventative strategies.</AbstractText><AbstractText Label="RECENT FINDINGS">Recently performed clinical trials and observational cohort studies underscore the high frequency of relapses of kidney disease, following initial response, in patients with proliferative and/or membranous lupus nephritis. Analysis of hard disease outcomes such as progression to chronic kidney disease or end-stage kidney disease, coupled with histological findings from repeat kidney biopsy studies, have drawn attention to the importance of renal function preservation that should be pursued as early as lupus nephritis is diagnosed. In this respect, non-randomized and randomized evidence have suggested a number of factors associated with reduced risk of renal flares such as attaining a very low level of proteinuria (&lt;&#x2009;700-800&#xa0;mg/24&#xa0;h by 12&#xa0;months), using mycophenolate over azathioprine, adding belimumab to standard therapy, maintaining immunosuppressive/biological treatment for at least 3 to 5&#xa0;years, and using hydroxychloroquine. Other factors that warrant further clarification include serological activity and the use of repeat kidney biopsy to guide the intensity and duration of treatment in selected cases. The results from ongoing innovative studies integrating kidney histological and clinical outcomes, together with an expanding spectrum of therapies in lupus nephritis, are expected to facilitate individual medical care and long-term disease and patient prognosis.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Banos</LastName><ForeName>Aggelos</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, 'Asklepieion' General Hospital, Voula, Athens, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Autoimmunity and Inflammation, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation Academy of Athens, 115 27, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertsias</LastName><ForeName>George</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-5299-1406</Identifier><AffiliationInfo><Affiliation>Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion and University of Crete Medical School, Voutes-Stavrakia, 71008, Heraklion, Greece. gbertsias@uoc.gr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Molecular Biology and Biotechnology-FORTH, Heraklion, Greece. gbertsias@uoc.gr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Rheumatol Rep</MedlineTA><NlmUniqueID>100888970</NlmUniqueID><ISSNLinking>1523-3774</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>MRK240IY2L</RegistryNumber><NameOfSubstance UI="D001379">Azathioprine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001379" MajorTopicYN="N">Azathioprine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biologic agents</Keyword><Keyword MajorTopicYN="N">End-stage kidney disease</Keyword><Keyword MajorTopicYN="N">Flares</Keyword><Keyword MajorTopicYN="N">Risk stratification</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">Therapeutic target</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>18</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>15</Day><Hour>21</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>15</Day><Hour>11</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37452914</ArticleId><ArticleId IdType="pmc">PMC10504124</ArticleId><ArticleId IdType="doi">10.1007/s11926-023-01109-6</ArticleId><ArticleId IdType="pii">10.1007/s11926-023-01109-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang H, Ren YL, Chang J, Gu L, Sun LY. A systematic review and meta-analysis of prevalence of biopsy-proven lupus nephritis. Arch Rheumatol. 2018;33(1):17&#x2013;25. doi: 10.5606/ArchRheumatol.2017.6127.</Citation><ArticleIdList><ArticleId IdType="doi">10.5606/ArchRheumatol.2017.6127</ArticleId><ArticleId IdType="pmc">PMC5864167</ArticleId><ArticleId IdType="pubmed">29900975</ArticleId></ArticleIdList></Reference><Reference><Citation>Gergianaki I, Fanouriakis A, Repa A, Tzanakakis M, Adamichou C, Pompieri A, et al. Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete. Greece Ann Rheum Dis. 2017;76(12):1992&#x2013;2000. doi: 10.1136/annrheumdis-2017-211206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211206</ArticleId><ArticleId IdType="pubmed">28780511</ArticleId></ArticleIdList></Reference><Reference><Citation>Delfino J, Dos Santos T, Skare TL. Comparison of lupus patients with early and late onset nephritis: a study in 71 patients from a single referral center. Adv Rheumatol. 2020;60(1):5. doi: 10.1186/s42358-019-0105-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42358-019-0105-5</ArticleId><ArticleId IdType="pubmed">31900216</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni G, Vercelloni PG, Quaglini S, Gatto M, Gianfreda D, Sacchi L, et al. Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann Rheum Dis. 2018;77(9):1318&#x2013;1325. doi: 10.1136/annrheumdis-2017-212732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-212732</ArticleId><ArticleId IdType="pubmed">29730634</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713&#x2013;723. doi: 10.1136/annrheumdis-2020-216924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-216924</ArticleId><ArticleId IdType="pubmed">32220834</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostopoulou M, Adamichou C, Bertsias G. An update on the diagnosis and management of lupus nephritis. Curr Rheumatol Rep. 2020;22(7):30. doi: 10.1007/s11926-020-00906-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-020-00906-7</ArticleId><ArticleId IdType="pubmed">32500443</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostopoulou M, Pitsigavdaki S, Bertsias G. Lupus nephritis: improving treatment options. Drugs. 2022;82(7):735&#x2013;748. doi: 10.1007/s40265-022-01715-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-022-01715-1</ArticleId><ArticleId IdType="pubmed">35486369</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertsias G. Recommendations for systemic lupus erythematosus: balancing evidence and eminence to facilitate the medical care of a complex disease. Rheum Dis Clin North Am. 2022;48(3):617&#x2013;636. doi: 10.1016/j.rdc.2022.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2022.05.001</ArticleId><ArticleId IdType="pubmed">35953227</ArticleId></ArticleIdList></Reference><Reference><Citation>Hocaoglu M, Valenzuela-Almada MO, Dabit JY, Osei-Onomah SA, Chevet B, Giblon RE, et al. Incidence, prevalence, and mortality of lupus nephritis: a population-based study over four decades using the lupus midwest network. Arthritis Rheumatol. 2023;75(4):567&#x2013;573. doi: 10.1002/art.42375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42375</ArticleId><ArticleId IdType="pmc">PMC10065880</ArticleId><ArticleId IdType="pubmed">36227575</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971&#x2013;2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol. 2016;68(6):1432&#x2013;1441. doi: 10.1002/art.39594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39594</ArticleId><ArticleId IdType="pmc">PMC5071782</ArticleId><ArticleId IdType="pubmed">26815601</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahajan A, Amelio J, Gairy K, Kaur G, Levy RA, Roth D, et al. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus. 2020;29(9):1011&#x2013;1020. doi: 10.1177/0961203320932219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320932219</ArticleId><ArticleId IdType="pmc">PMC7425376</ArticleId><ArticleId IdType="pubmed">32571142</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanou A, Jupe E, Purushothaman M, Niewold TB, Munroe ME. Clinical disease activity and flare in SLE: current concepts and novel biomarkers. J Autoimmun. 2021;119:102615. doi: 10.1016/j.jaut.2021.102615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102615</ArticleId><ArticleId IdType="pmc">PMC8044029</ArticleId><ArticleId IdType="pubmed">33631651</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamichou C, Bertsias G. Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies. Mediterr J Rheumatol. 2017;28(1):4&#x2013;12. doi: 10.31138/mjr.28.1.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.31138/mjr.28.1.4</ArticleId><ArticleId IdType="pmc">PMC7045928</ArticleId><ArticleId IdType="pubmed">32185248</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamirou F, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Fiehn C, et al. Long-term follow-up of the MAINTAIN nephritis trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis. 2016;75(3):526&#x2013;531. doi: 10.1136/annrheumdis-2014-206897.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-206897</ArticleId><ArticleId IdType="pmc">PMC4789692</ArticleId><ArticleId IdType="pubmed">25757867</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Furie R, Teng YKO, Contreras G, Malvar A, Yu X, et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022;101(2):403&#x2013;413. doi: 10.1016/j.kint.2021.08.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.08.027</ArticleId><ArticleId IdType="pubmed">34560137</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriens C, Parikh S, Hodge L, Mela C, Leher H. Assessment of long-term safety and efficacy including renal outcome over three years of treatment in the phase 3 AURORA 1 and AURORA 2 studies.&#xa0;[abstract]. Arthritis Rheumatol. 2022;74 (suppl 9).</Citation></Reference><Reference><Citation>Pirson V, Enfrein A, Houssiau FA, Tamirou F. Absence of renal remission portends poor long-term kidney outcome in lupus nephritis. Lupus Sci Med.&#xa0;2021;8(1): e000533.&#xa0;10.1136/lupus-2021-000533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8395364</ArticleId><ArticleId IdType="pubmed">34446568</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapsia E, Marinaki S, Michelakis I, Liapis G, Sfikakis PP, Boletis J, et al. Predictors of early response, flares, and long-term adverse renal outcomes in proliferative lupus nephritis: a 100-month median follow-up of an inception cohort.&#xa0;J Clin Med. 2022;11(17):5017.&#xa0;10.3390/jcm11175017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9457419</ArticleId><ArticleId IdType="pubmed">36078950</ArticleId></ArticleIdList></Reference><Reference><Citation>Luis MSF, Bultink IEM, da Silva JAP, Voskuyl AE, Ines LS. Early predictors of renal outcome in patients with proliferative lupus nephritis: a 36-month cohort study. Rheumatology (Oxford) 2021;60(11):5134&#x2013;5141. doi: 10.1093/rheumatology/keab126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab126</ArticleId><ArticleId IdType="pubmed">33560332</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC, Ho LY, Ying SKY, Leung MC, To CH, Ng WL. Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Ann Rheum Dis. 2020;79(8):1070&#x2013;1076. doi: 10.1136/annrheumdis-2020-217178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217178</ArticleId><ArticleId IdType="pubmed">32448782</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto M, Kitamura M, Sato S, Fujikawa K, Horai Y, Matsuoka N, et al. Life prognosis and renal relapse after induction therapy in Japanese patients with proliferative and pure membranous lupus nephritis. Rheumatology (Oxford) 2021;60(5):2333&#x2013;2341. doi: 10.1093/rheumatology/keaa599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa599</ArticleId><ArticleId IdType="pubmed">33166998</ArticleId></ArticleIdList></Reference><Reference><Citation>Momtaz M, Fayed A, Wadie M, Gamal SM, Ghoniem SA, Sobhy N, et al. Retrospective analysis of nephritis response and renal outcome in a cohort of 928 Egyptian lupus nephritis patients: a university hospital experience. Lupus. 2017;26(14):1564&#x2013;1570. doi: 10.1177/0961203317716320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317716320</ArticleId><ArticleId IdType="pubmed">28625079</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap DYH, Tang C, Ma MKM, Mok MMY, Chan GCW, Kwan LPY, et al. Longterm data on disease flares in patients with proliferative lupus nephritis in recent years. J Rheumatol. 2017;44(9):1375&#x2013;1383. doi: 10.3899/jrheum.170226.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.170226</ArticleId><ArticleId IdType="pubmed">28668803</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, Acevedo-Vasquez E, Alarcon GS, Pastor-Asurza CA, Alfaro-Lozano JL, Cucho-Venegas JM, et al. The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Ann Rheum Dis. 2015;74(6):1019&#x2013;1023. doi: 10.1136/annrheumdis-2013-204620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-204620</ArticleId><ArticleId IdType="pubmed">24525909</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatto M, Radice F, Saccon F, Calatroni M, Frontini G, Trezzi B, et al. Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis.&#xa0;Lupus Science &amp; Medicine 2022;9:e000689. 10.1136/lupus-2022-000689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9109114</ArticleId><ArticleId IdType="pubmed">35568438</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022; Moroni G, Porata G, Raffiotta F, Frontini G, Calatroni M, Reggiani F, et al. Predictors of increase in chronicity index and of kidney function impairment at repeat biopsy in lupus nephritis.&#xa0;Lupus Science &amp; Medicine 2022;9:e000721. 10.1136/lupus-2022-000721. One of the largest European cohorts of lupus nephritis which identifies predictors of clinical and histological deterioration at repeat kidney biopsy.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9386217</ArticleId><ArticleId IdType="pubmed">35973744</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7. doi: 10.1038/s41572-019-0141-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0141-9</ArticleId><ArticleId IdType="pubmed">31974366</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijnink EC, Teng YKO, Wilhelmus S, Almekinders M, Wolterbeek R, Cransberg K, et al. Clinical and histopathologic characteristics associated with renal outcomes in lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):734&#x2013;743. doi: 10.2215/CJN.10601016.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.10601016</ArticleId><ArticleId IdType="pmc">PMC5477219</ArticleId><ArticleId IdType="pubmed">28473317</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh SV, Nagaraja HN, Hebert L, Rovin BH. Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis. Clin J Am Soc Nephrol. 2014;9(2):279&#x2013;284. doi: 10.2215/CJN.05040513.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.05040513</ArticleId><ArticleId IdType="pmc">PMC3913239</ArticleId><ArticleId IdType="pubmed">24262502</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Arias AA, Marquez-Macedo SE, Pena-Vizcarra OR, Zavala-Miranda MF, Romero-Diaz J, Morales-Buenrostro LE, et al. The influence of repeated flares in response to therapy and prognosis in lupus nephritis. Nephrol Dial Transplant. 2023;38(4):884&#x2013;893. doi: 10.1093/ndt/gfac304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfac304</ArticleId><ArticleId IdType="pubmed">36318456</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejia-Vilet JM, Cordova-Sanchez BM, Arreola-Guerra JM, Morales-Buenrostro LE, Uribe-Uribe NO, Correa-Rotter R. Renal flare prediction and prognosis in lupus nephritis Hispanic patients. Lupus. 2016;25(3):315&#x2013;324. doi: 10.1177/0961203315606985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203315606985</ArticleId><ArticleId IdType="pubmed">26405028</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C. &#x201c;Nephritic flares&#x201d; are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int. 1996;50(6):2047&#x2013;2053. doi: 10.1038/ki.1996.528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1996.528</ArticleId><ArticleId IdType="pubmed">8943489</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosca M, Bencivelli W, Neri R, Pasquariello A, Batini V, Puccini R, et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int. 2002;61(4):1502&#x2013;1509. doi: 10.1046/j.1523-1755.2002.00280.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1523-1755.2002.00280.x</ArticleId><ArticleId IdType="pubmed">11918758</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolly M, Galicier L, Aumaitre O, Frances C, Le Guern V, Liote F, et al. Quality of life in systemic lupus erythematosus: description in a cohort of French patients and association with blood hydroxychloroquine levels. Lupus. 2016;25(7):735&#x2013;740. doi: 10.1177/0961203315627200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203315627200</ArticleId><ArticleId IdType="pubmed">26876692</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell CF, Huang SP, Cyhaniuk A, Averell CM. The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States. Lupus. 2023;32(2):301&#x2013;309. doi: 10.1177/09612033221146093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221146093</ArticleId><ArticleId IdType="pmc">PMC9939932</ArticleId><ArticleId IdType="pubmed">36542670</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson JC, Mahajan A, Scott DA, Gairy K. The economic burden of lupus nephritis: a systematic literature review. Rheumatol Ther. 2022;9(1):25&#x2013;47. doi: 10.1007/s40744-021-00368-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40744-021-00368-y</ArticleId><ArticleId IdType="pmc">PMC8814085</ArticleId><ArticleId IdType="pubmed">34731412</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertsias G, Karampli E, Sidiropoulos P, Gergianaki I, Drosos A, Sakkas L, et al. Clinical and financial burden of active lupus in Greece: a nationwide study. Lupus. 2016;25(12):1385&#x2013;1394. doi: 10.1177/0961203316642310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316642310</ArticleId><ArticleId IdType="pubmed">27055520</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Huang S, Chen T, Liang D, Yang J, Zeng C, et al. Machine learning for prediction and risk stratification of lupus nephritis renal flare. Am J Nephrol. 2021;52(2):152&#x2013;160. doi: 10.1159/000513566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000513566</ArticleId><ArticleId IdType="pubmed">33744876</ArticleId></ArticleIdList></Reference><Reference><Citation>Portalatin GM, Gebreselassie SK, Bobart SA. Lupus nephritis - an update on disparities affecting african americans. J Natl Med Assoc. 2022;114(3S2):S34&#x2013;S42. doi: 10.1016/j.jnma.2022.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jnma.2022.05.005</ArticleId><ArticleId IdType="pmc">PMC9168792</ArticleId><ArticleId IdType="pubmed">35595581</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciruelo E, de la Cruz J, Lopez I, Gomez-Reino JJ. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum. 1996;39(12):2028&#x2013;2034. doi: 10.1002/art.1780391212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780391212</ArticleId><ArticleId IdType="pubmed">8961908</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon SJ, Park HS, Kwok SK, Ju JH, Choi BS, Park KS, et al. Predictors of renal relapse in Korean patients with lupus nephritis who achieved remission six months following induction therapy. Lupus. 2013;22(5):527&#x2013;537. doi: 10.1177/0961203313476357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313476357</ArticleId><ArticleId IdType="pubmed">23423249</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon OC, Cho YM, Oh JS, Hong S, Lee CK, Yoo B, et al. Renal flare in class V lupus nephritis: increased risk in patients with tubulointerstitial lesions. Rheumatol Int. 2019;39(12):2061&#x2013;2067. doi: 10.1007/s00296-019-04369-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-019-04369-7</ArticleId><ArticleId IdType="pubmed">31280358</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang KC, Lin CH, Chen PL, Wu YH, Hou CW, Huang JA. Severe lupus flare is associated with a much higher risk of stroke among patients with SLE.&#xa0;Int J Stroke. 2023;0(0). 10.1177/17474930231174227.</Citation><ArticleIdList><ArticleId IdType="pubmed">37089085</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, et al. Definition and initial validation of a lupus low disease activity state (LLDAS) Ann Rheum Dis. 2016;75(9):1615&#x2013;1621. doi: 10.1136/annrheumdis-2015-207726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207726</ArticleId><ArticleId IdType="pubmed">26458737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisaoglu H, Baba O, Kalyoncu M. Lupus low disease activity state as a treatment target for pediatric patients with lupus nephritis. Pediatr Nephrol. 2023;38(4):1167&#x2013;1175. doi: 10.1007/s00467-022-05742-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-022-05742-8</ArticleId><ArticleId IdType="pubmed">36156735</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichinose K, Kitamura M, Sato S, Eguchi M, Okamoto M, Endo Y, et al. Complete renal response at 12 months after induction therapy is associated with renal relapse-free rate in lupus nephritis: a single-center, retrospective cohort study. Lupus. 2019;28(4):501&#x2013;509. doi: 10.1177/0961203319829827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319829827</ArticleId><ArticleId IdType="pubmed">30755146</ArticleId></ArticleIdList></Reference><Reference><Citation>Won J, Lee JS, Oh JS, Kim YG, Lee CK, Yoo B, et al. Impact of stringent response in proteinuria on long-term renal outcomes in proliferative lupus nephritis. Lupus. 2019;28(11):1294&#x2013;1301. doi: 10.1177/0961203319876695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319876695</ArticleId><ArticleId IdType="pubmed">31583978</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K. Early achievement of deep remission predicts low incidence of renal flare in lupus nephritis class III or IV. Arthritis Res Ther. 2018;20(1):86. doi: 10.1186/s13075-018-1576-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-018-1576-1</ArticleId><ArticleId IdType="pmc">PMC5932878</ArticleId><ArticleId IdType="pubmed">29720229</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ, Collaborative Study G Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008;3(1):46&#x2013;53. doi: 10.2215/CJN.03280807.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.03280807</ArticleId><ArticleId IdType="pmc">PMC2390978</ArticleId><ArticleId IdType="pubmed">18003764</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni G, Gatto M, Tamborini F, Quaglini S, Radice F, Saccon F, et al. Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. Ann Rheum Dis. 2020;79(8):1077&#x2013;1083. doi: 10.1136/annrheumdis-2020-216965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-216965</ArticleId><ArticleId IdType="pubmed">32503858</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanaoka H, Yamada H, Kiyokawa T, Iida H, Suzuki T, Yamasaki Y, et al. Lack of partial renal response by 12 weeks after induction therapy predicts poor renal response and systemic damage accrual in lupus nephritis class III or IV. Arthritis Res Ther. 2017;19(1):4. doi: 10.1186/s13075-016-1202-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-016-1202-z</ArticleId><ArticleId IdType="pmc">PMC5237142</ArticleId><ArticleId IdType="pubmed">28086993</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958&#x2013;967. doi: 10.1136/annrheumdis-2013-205139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205139</ArticleId><ArticleId IdType="pubmed">24739325</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo AL, Kandane-Rathnayake R, Koelmeyer R, Golder V, Louthrenoo W, Chen YH, et al. SMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus - an analysis of anti-double-stranded DNA monitoring. Rheumatology (Oxford) 2023 doi: 10.1093/rheumatology/kead231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kead231</ArticleId><ArticleId IdType="pubmed">37208196</ArticleId></ArticleIdList></Reference><Reference><Citation>Golder V, Kandane-Rathnayake R, Huq M, Louthrenoo W, Luo SF, Wu Y-JJ, et al. Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study. Lancet Rheumatol. 2019;1:e103&#x2013;e10. doi: 10.1016/S2665-9913(19)30048-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(19)30048-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostopoulou M, Ugarte-Gil MF, Pons-Estel B, van Vollenhoven RF, Bertsias G. The association between lupus serology and disease outcomes: a systematic literature review to inform the treat-to-target approach in systemic lupus erythematosus. Lupus. 2022;31(3):307&#x2013;318. doi: 10.1177/09612033221074580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221074580</ArticleId><ArticleId IdType="pubmed">35067068</ArticleId></ArticleIdList></Reference><Reference><Citation>Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886&#x2013;1895. doi: 10.1056/NEJMoa1014460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1014460</ArticleId><ArticleId IdType="pubmed">22087680</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez A, Jagerback S, Sjowall C, Parodis I. Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials. Rheumatology (Oxford) 2023 doi: 10.1093/rheumatology/kead253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kead253</ArticleId><ArticleId IdType="pubmed">37228028</ArticleId></ArticleIdList></Reference><Reference><Citation>Jourde-Chiche N, Costedoat-Chalumeau N, Baumstarck K, Loundou A, Bouillet L, Burtey S, et al. Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. Ann Rheum Dis. 2022;81(10):1420&#x2013;1427. doi: 10.1136/annrheumdis-2022-222435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-222435</ArticleId><ArticleId IdType="pmc">PMC9484365</ArticleId><ArticleId IdType="pubmed">35725295</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford) 2020;59(Suppl5):v69&#x2013;v81. doi: 10.1093/rheumatology/keaa403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa403</ArticleId><ArticleId IdType="pmc">PMC7719039</ArticleId><ArticleId IdType="pubmed">33280011</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni G, Gatto M, Raffiotta F, Binda V, Frangou E, Lightstone L, et al. Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate. Autoimmun Rev. 2018;17(1):11&#x2013;18. doi: 10.1016/j.autrev.2017.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2017.11.003</ArticleId><ArticleId IdType="pubmed">29108824</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade Balbi V, Artur Silva C, NascimentoPedrosa T, Maria Rodrigues Pereira R, Maria de Arruda Campos L, Pires Leon E, et al. Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis. Lupus. 2022;31(1):97&#x2013;104. doi: 10.1177/09612033211062515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211062515</ArticleId><ArticleId IdType="pubmed">34965782</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha C, Alexander S, Ashby D, Lee J, Chusney G, Cairns TD, et al. Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome? Nephrol Dial Transplant. 2018;33(9):1604&#x2013;1610. doi: 10.1093/ndt/gfx318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfx318</ArticleId><ArticleId IdType="pmc">PMC7170714</ArticleId><ArticleId IdType="pubmed">29186572</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikoloudaki M, Repa A, Pitsigavdaki S, Sali AMI, Sidiropoulos P, Lionis C, et al. Correction: Nikoloudaki et al. Persistence of depression and anxiety despite short-term disease activity improvement in patients with systemic lupus erythematosus: a single-centre, prospective study. J Clin Med. 2023;12(1):227. 10.3390/jcm12010227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9821675</ArticleId><ArticleId IdType="pubmed">36615195</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy C, Gladman DD, Su J, Rozenbojm N, Urowitz MB. Barriers to medication adherence and degree of nonadherence in a systemic lupus erythematosus (SLE) outpatient population. Rheumatol Int. 2021;41(8):1457&#x2013;1464. doi: 10.1007/s00296-021-04898-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-021-04898-0</ArticleId><ArticleId IdType="pubmed">34089358</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali AY, Abdelaziz TS, Behiry ME. The prevalence and causes of non-adherence to immunosuppressive medications in patients with lupus nephritis flares. Curr Rheumatol Rev. 2020;16(3):245&#x2013;248. doi: 10.2174/1573397115666190626111847.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573397115666190626111847</ArticleId><ArticleId IdType="pubmed">31241434</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodis I, Adamichou C, Aydin S, Gomez A, Demoulin N, Weinmann-Menke J, et al. Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis. Rheumatology (Oxford) 2020;59(11):3424&#x2013;3434. doi: 10.1093/rheumatology/keaa129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa129</ArticleId><ArticleId IdType="pubmed">32353879</ArticleId></ArticleIdList></Reference><Reference><Citation>Lledo-Ibanez GM, Xipell M, Ferreira M, Sole M, Garcia-Herrera A, Cervera R, et al. Kidney biopsy in lupus nephritis after achieving clinical renal remission: paving the way for renal outcome assessment. Clin Kidney J. 2022;15(11):2081&#x2013;2088. doi: 10.1093/ckj/sfac150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ckj/sfac150</ArticleId><ArticleId IdType="pmc">PMC9613421</ArticleId><ArticleId IdType="pubmed">36325009</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rosa M, Azzato F, Toblli JE, De Rosa G, Fuentes F, Nagaraja HN, et al. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int. 2018;94(4):788&#x2013;794. doi: 10.1016/j.kint.2018.05.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2018.05.021</ArticleId><ArticleId IdType="pubmed">30045812</ArticleId></ArticleIdList></Reference><Reference><Citation>Munroe ME, Blankenship D, DeFreese D, Purushothaman M, DeJager W, Macwana S, et al. A flare risk index informed by select immune mediators in systemic lupus erythematosus. Arthritis Rheumatol. 2023;75(5):723&#x2013;735. doi: 10.1002/art.42389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42389</ArticleId><ArticleId IdType="pmc">PMC10106527</ArticleId><ArticleId IdType="pubmed">36245261</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Rojas MA, Sanchez-Navarro A, Mejia-Vilet JM, Perez-Villalva R, Uribe N, Bobadilla NA. Urinary serpin-A3 is an early predictor of clinical response to therapy in patients with proliferative lupus nephritis. Am J Physiol Renal Physiol. 2022;323(4):F425&#x2013;F434. doi: 10.1152/ajprenal.00099.2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.00099.2022</ArticleId><ArticleId IdType="pubmed">35834275</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Wu L, Su H, Feng X, Shi M, Jin L, et al. Association of urinary matrix metalloproteinase 7 levels with incident renal flare in lupus nephritis. Arthritis Rheumatol. 2021;73(2):265&#x2013;275. doi: 10.1002/art.41506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41506</ArticleId><ArticleId IdType="pubmed">32892475</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanarsa K, Soomro S, Zhang T, Strachan B, Pedroza C, Nidhi M, et al. Quantitative planar array screen of 1000 proteins uncovers novel urinary protein biomarkers of lupus nephritis. Ann Rheum Dis. 2020;79(10):1349&#x2013;1361. doi: 10.1136/annrheumdis-2019-216312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-216312</ArticleId><ArticleId IdType="pmc">PMC7839323</ArticleId><ArticleId IdType="pubmed">32651195</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejia-Vilet JM, Zhang XL, Cruz C, Cano-Verduzco ML, Shapiro JP, Nagaraja HN, et al. Urinary soluble CD163: a novel noninvasive biomarker of activity for lupus nephritis. J Am Soc Nephrol. 2020;31(6):1335&#x2013;1347. doi: 10.1681/ASN.2019121285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2019121285</ArticleId><ArticleId IdType="pmc">PMC7269356</ArticleId><ArticleId IdType="pubmed">32300067</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasano S, Pierro L, Borgia A, Coscia MA, Formica R, Bucci L, et al. Biomarker panels may be superior over single molecules in prediction of renal flares in systemic lupus erythematosus: an exploratory study. Rheumatology (Oxford) 2020;59(11):3193&#x2013;3200. doi: 10.1093/rheumatology/keaa074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa074</ArticleId><ArticleId IdType="pubmed">32211780</ArticleId></ArticleIdList></Reference><Reference><Citation>Cody EM, Bennett MR, Gulati G, Ma Q, Altaye M, Devarajan P, et al. Successful urine multiplex bead assay to measure lupus nephritis activity. Kidney Int Rep. 2021;6(7):1949&#x2013;1960. doi: 10.1016/j.ekir.2021.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2021.04.016</ArticleId><ArticleId IdType="pmc">PMC8258454</ArticleId><ArticleId IdType="pubmed">34307989</ArticleId></ArticleIdList></Reference><Reference><Citation>Cody EM, Wenderfer SE, Sullivan KE, Kim AHJ, Figg W, Ghumman H, et al. Urine biomarker score captures response to induction therapy with lupus nephritis. Pediatr Nephrol. 2023 doi: 10.1007/s00467-023-05888-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-023-05888-z</ArticleId><ArticleId IdType="pmc">PMC10393841</ArticleId><ArticleId IdType="pubmed">36715772</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa-Reis P, Maurer K, Petri MA, Levy Erez D, Zhao X, Faig W, et al. Urinary HER2, TWEAK and VCAM-1 levels are associated with new-onset proteinuria in paediatric lupus nephritis.&#xa0;Lupus Sci Med 2022;9:e000719. 10.1136/lupus-2022-000719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9351344</ArticleId><ArticleId IdType="pubmed">35918102</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>